Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

VExUS Combined With CVP to Predict Clinical Outcomes in Sepsis Participants

Venous Excess Ultrasound Score (VExUS) Combined With Central Venous Pressure (CVP) to Predict Clinical Outcomes in Sepsis Participants

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Introduction: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host immune response to infection, and it is a common critical condition in the ICU. Early and timely fluid resuscitation is the cornerstone of sepsis treatment. However, excessive fluid loading can lead to interstitial edema and iatrogenic organ damage, particularly acute kidney injury (AKI). The VExUS grading system is a recently developed system that measures venous congestion through bedside ultrasound by assessing the blood flow waveforms of the portal vein, hepatic vein, and intrarenal veins, as well as the diameter of the inferior vena cava. Similarly, CVP is a commonly used indicator of venous congestion. The objective of this study is to Investigate the association between Venous Excess Ultrasound Score (VExUS), Central Venous Pressure (CVP) during the first three days of ICU admission, and the composite clinical outcome of major adverse kidney events within 30 days (MAKE 30) in sepsis participants. Methods: This study is a prospective, multicenter, observational study that will recruit at least 120 participants across multiple centers. Based on the definition of sepsis3.0, Participants with sepsis who are older than 18 years. Using Doppler ultrasound, Investigator will measure the IVC, HV, PV, and IRV, as well as lung ultrasound scores and cardiac-related parameters at 0-24 hours, 24-48 hours, and 48-72 hours after enrollment. Investigator will receive web-based educational courses, and image acquisition and interpretation will be adjudicated. The primary outcome is the relationship between VExUS score combined with CVP and MAKE 30 in sepsis participants.

Who May Be Eligible (Plain English)

Who May Qualify: - Adult participants (age ≥ 18 years) with sepsis upon admission or during their stay in the ICU. Who Should NOT Join This Trial: - Age \< 18 years - Participants admitted to the ICU for \< 24 hours - Pregnant or lactating women - Severe renal impairment (defined as baseline estimated glomerular filtration rate \< 15 mL/min or requiring regular dialysis), including causes such as urinary tract obstruction, contrast agents, or nephrotoxic drugs - Liver cirrhosis with portal hypertension - Presence of urinary tract obstruction (which may affect IRVF waveform) - Inability to resolve the primary disease - Participants receiving palliative care - Inability to obtain ultrasound images - Inability to monitor CVP - Refusal of monitoring by participants or their families Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Adult participants (age ≥ 18 years) with sepsis upon admission or during their stay in the ICU. Exclusion Criteria: * Age \< 18 years * Participants admitted to the ICU for \< 24 hours * Pregnant or lactating women * Severe renal impairment (defined as baseline estimated glomerular filtration rate \< 15 mL/min or requiring regular dialysis), including causes such as urinary tract obstruction, contrast agents, or nephrotoxic drugs * Liver cirrhosis with portal hypertension * Presence of urinary tract obstruction (which may affect IRVF waveform) * Inability to resolve the primary disease * Participants receiving palliative care * Inability to obtain ultrasound images * Inability to monitor CVP * Refusal of monitoring by participants or their families

Treatments Being Tested

DEVICE

Point-of-care ultrasound (POCUS)

Point-of-care ultrasound (POCUS) measurements will be performed for all participants

Locations (1)

Point-of-care ultrasound (POCUS)
Yibin, Sichuan, China